Cahir MedTech
Cahir MedTech Product Suite

Advancing MedTech InnovationAI-powered Strategy and execution for MedTech

CAHIR MedTech builds AI workspaces that help MedTech teams move their ideas from initial concepts to working prototypes more predictably and drive strategic growth faster with actionable and defensible market intelligence.

Global regulatory markets mapped
25+
Global regulatory markets mapped
FDA AI-enabled device & PCCP updates
Live
FDA AI-enabled device & PCCP updates
QMSR & eSTAR audit toolkits
Turnkey
QMSR & eSTAR audit toolkits

From market decision to submission clarity

Most MedTech teams face two disconnected questions: where to launch and how to get regulatory-ready. CAHIR's AI products answer both in connected workspaces.

Strategy

MedTech Compass

Compliance

MedTech Copilot

Founder roadmap

From concept to clearance

A continuous lifecycle for founders and innovators. Jump in at any stage, and come back around whenever you have new questions.

Your device lifecycle

DevicePath

Phase 1 of 4

Phase 1 · DevicePath

Pathway & Predicate Triage

Describe your device and get its likely FDA class, candidate product codes, probable pathway and real 510(k) predicate candidates.

Highly recommended: Go deeper with the MedCompass Premium Regulatory Analyzer for a pathway analysis built on vetted sources.

What you get

  • Likely FDA class & product codes
  • 510(k), De Novo, PMA or exempt pathway
  • Predicate candidates with K-numbers

Still have questions at this stage?

Ask our team about this stage

Not sure where to begin? Contact our team at medtech@cahir.ai — we bring decades of medtech commercialization experience to every engagement.

Services included with your engagement

The CAHIR Pathway

Four advisory stages our experts and partners walk through with you, from the first clinical signal to successful market integration.

The pathway closes where it matters — approval, coverage, adoption, and revenue: successful market integration.

Across the device lifecycle

Device Class Support

From implantable devices to digital health, connect regulatory development with market access through MedTech Copilot and MedTech Compass.

Illustration of an ECG smartwatch connected to AI health dashboards

Class II / De Novo

SaMD & Digital Health

Software classification, clinical validation and pathways for connected and AI-enabled devices.

Illustration of a laboratory diagnostic analyzer with sample vials

510(k) / De Novo

Diagnostic / IVD

Predicate assessment, analytical performance and clinical evidence for diagnostic technologies.

Technical illustration of a hip implant and spinal fixation hardware

Class III / PMA

High-Risk Implantable

Evidence planning, risk management and premarket approval strategy for high-risk implants.

Orthopedic device pathway
Wireframe illustration of an MRI scanner and surgical robot

Imaging / Robotics

Capital Equipment

Regulatory strategy, hospital purchasing and total-cost-of-ownership insights for major systems.

Illustration of single-use syringe, IV set, glove and sterile-packed instrument

High Volume

Consumable / Disposable

Device-specific pathways, procurement economics and adoption planning for high-volume products.

Editorial illustration of an injection pen, vascular stent and medication vial

Drug–device combination products

Combination Products

Primary mode of action, constituent-part requirements and evidence planning for drug–device combination products.

Categories illustrate areas of support, not fixed classifications. The applicable FDA class and pathway depend on intended use, risk and available predicates; De Novo generally establishes Class I or II classification. Combination-product jurisdiction and requirements depend on the primary mode of action and constituent parts.

Two engines. One approach built on vetted sources.

Development engine

MedTech Copilot

Requirements, design history and quality documentation, structured for regulatory readiness.

RequirementsDHFV&VDoc control

Intelligence engine

MedTech Compass

Pathways, reimbursement, competition and market opportunity, prioritized for adoption.

PathwaysReimbursementCompetitionMarkets

Shared evidence foundation

Device-specific triage and pathways

Frame regulatory and market-access questions around your device’s intended use, risk profile and target markets.

Built for informed decisions you can trust and verify. Outputs support expert review; they do not replace regulatory, clinical or reimbursement advice.

Workspace

One workspace for your whole team

The Cahir MedTech Workspace brings your toolkits, checklists, notes and team history together on one screen, so regulatory and quality work moves forward in one place.

Toolkit library

Every toolkit your company has unlocked, in one shared place for the whole team.

Live checklists

Work through each toolkit item by item and see progress update for everyone.

Notes on each item

Leave notes on any item so reviewers and auditors see the context behind the work.

Activity history

See who changed what and when. Every name and time is recorded automatically.

Up and running in minutes

  1. 1

    Use your work email

    Sign up with a password or a one-click email link. No password needed if you prefer.

  2. 2

    Your company is set up for you

    We create your company workspace automatically from your email domain.

  3. 3

    Colleagues join automatically

    Teammates with the same work email domain land in the same workspace.

Market reality

Medical device development is often complex and time intensive

Bringing a device to market takes years and serious capital, and every step needs evidence. Here is what founders are up against, and where Cahir helps.

Development timeline

Years

Hover or tap for details

Development timeline

Years

Concept to U.S. market takes years, and longest for PMA devices that need clinical studies

Source: Makower et al., Stanford (2010)

With Cahir

Pathway and predicate triage up front so teams don't take the wrong route.

Capital required

$31M / $94M

Hover or tap for details

Capital required

$31M / $94M

Average cost from concept to market: 510(k) vs. PMA devices

Source: Makower et al., Stanford (2010)

With Cahir

Structured evidence drafting cuts down rework between milestones.

Review deficiencies

Clock stops

Hover or tap for details

Reimbursement lag

≤5 / yr

Hover or tap for details

Reimbursement lag

≤5 / yr

Breakthrough devices CMS will accept each year into its TCET expedited coverage pathway

Source: CMS TCET final notice (2024)

With Cahir

Global market and reimbursement mapping from early in development.

The Commercialization Chasm

Pick a challenge to see how Cahir helps.

Funding gaps between proof-of-concept, verification and clinical milestones.

How Cahir accelerates the crossing

Defensible regulatory milestones mapped early for pitch decks and tranche planning.

Explore DevicePath & MedTech Compass
AI Device Evaluation

You need more than AI vendor demos.

Our five-phase framework helps health systems, buyers and partners evaluate AI-enabled medical devices before capital is committed, then oversee them after go-live.

5

Advisory phases

40/35/25

Clinical · technical · operational

100

Point Procurement Readiness Score

  1. 1. Governance Readiness
  2. 2. Market Assessment
  3. 3. Evaluation & Scoring
  4. 4. Pilot & Decision
  5. 5. Post-Deployment
Five-phase AI device evaluation pathway
AI-Enabled Medical Devices

AI-enabled medical device updates

New FDA authorizations from the AI-Enabled Medical Devices list and radiology AI news from RadAISlice — each linking to the full original record or article.

Automatically refreshes every 24 hoursAI devices with PCCPs
Live AI device wire
AI devicesJust announced
Deep Learning on PSMA-PET Scans Predicts Survival in Prostate Cancer

Deep learning models applied to PSMA-PET scans outperform existing tools in predicting two-year survival for metastatic prostate cancer.

MedTech term lookup

From concept to market. Every term, decoded.

Explore 103 terms across development, manufacturing, supply chains, clinical evidence and commercialization — with primary sources.

Device category

103 relevant terms · Cross-device topics included

Popular terms

AI and software

PCCP

Predetermined Change Control Plan

A Predetermined Change Control Plan (PCCP) is the part of a marketing submission that describes planned device modifications, how they will be developed and validated, and their impact assessment, so authorized changes can be made without a new submission.

Why it matters for founders

For AI/ML devices, an authorized PCCP lets you update models faster — but every change must still be executed under your quality system.

Related terms

AI/ML PCCP Suite

$399 USD · One-time · Applicable taxes may apply

Buy the Kit
Security

Enterprise-grade security

One security foundation. Every product.

Infrastructure
Certified cloud hosting
Access
Only your team gets in
Payments
Card data never touches us

Your strategy, design records and market intelligence stay yours.

Medical device professional reviewing secured regulatory data on a laptop

Certified infrastructure

Hosted on cloud infrastructure that maintains SOC 2 Type II and ISO 27001:2022 certifications.

Organization-scoped isolation

Row Level Security scopes every record to your organization. No cross-tenant access, by policy and by design.

PCI-DSS payments

Payments processed by Stripe (PCI-DSS Level 1). Card and bank details never touch CAHIR servers.

Collaborating Across the MedTech Ecosystem With Integrity & Trust

  • AdvaMed
  • U.S. Food and Drug Administration
  • BioTechX
  • U.S. Department of Health & Human Services
  • MedTech World
  • HLTH
  • HL7 International
  • Florida Medical Manufacturers' Consortium
  • GMDN Agency
  • Moffitt Cancer Center
  • MedtechWOMEN
  • WomenTech Network
  • DiMe — Digital Medicine Society
  • MedTech Innovator